

## UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 2-12-12003

Date of Deposit

Signature

EL 964832244 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO .: DEAV2002/0087 US NP

INVENTORS: Wendelin Frick et al

TITLE: NOVEL HETEROCYCLIC

FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF

\*Fee Transmittal Form (e.g., PTO/SB/17)

**APPLICATION ELEMENTS** 

17548 U.S.PTC 10/734573
-------------------------

		(Submit an original and a duplicate for fee processing)		
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	63
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	
4.	Oath	or Declaration	Total Pages	2
	a.	Newly executed (Unexecuted)		
	b.	Copy from a prior application (37 CFR § 1  i. DELETION OF INVENTOR(S)	.63(d))	
		Signed statement attached deleting i application, see 37 CFR §§ 1.63(d)(2		ned in the prior
5.	Pow	er of Attorney	Total Pages	
	a.	Newly executed (original or copy)		
	b.	Copy from a prior application (37 CFR § 1	.63(d))	
6.		Microfiche Computer Program (Appendix)		

Applie Page 2	cation Transmittal Letter	
7.	Nucleotide and/or Amino Acid Sequer (if applicable, all necessary)  a. Computer Readable Copy	
	b. Paper Copy (identical to co	
	c. Statement verifying identity	
	o oratement verifying identity	y or above depice
	Continuation Divisional of prior application no:, filed	k appropriate box, and supply the requisite information:  Continuation-in-part
	Examiner, Group/Art Unit (The cross reference has been/will be	inserted on page one of the specification).
Dece	filed April 29, 2003 and claims priori	U.S. Provisional Application No. 60/466,449, ty to Germany Application No. 10258008.1-43, filed peen/will be inserted on page one of the specification).
	Incorporation By Reference (useable	if filing a continuation/divisional and a copy of the declaration from the prior
		ication, from which a copy of the oath or declaration is of the disclosure of the accompanying application and is rein.
ACC	OMPANYING APPLICATION PARTS	
7.	Assignment Papers (cover sheet &	document(s))
8.	37 CFR §3.73(b) Statement	
0	(when there is an assignee)	nument (if applicable)
9. 10	Verified English Translation Doc Information Disclosure	Copies of IDS Citations
10.	Statement (IDS)/PTO-1449	Copies of IDS Citations
11.	Preliminary Amendment	
12.	Return Receipt Postcard (MPEF (Should be specifically itemized)	
13.	*Small Entity Statement(s)	Statement filed in prior application,
14.	(PTO/SB/09-12)  Certified Copy of Priority Docum	Status still proper and desired nent(s) (DE 10258008.1-43)
	(if foreign priority is claimed)	
15.	Other: E-Pave Application Da	ta Sneet
COR	RESPONDENCE ADDRESS	
$\boxtimes$	Customer Number or Bar Code Label	005487
		(Insert Customer No. or Attach bar code label here)
		ROEK
		Barbara E. Kurys, Reg. No. 34,650
		Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0087 US NP

information unless it displays a valid OiviB control number

Under the Paperwork Reduction Act or 1995, no persons are required to respond to a collection of **FEE TRANSMITTAL** 

Complete if Known **NOT YET ASSIGNED** Application Number **FILED HEREWITH** Filing Date Wendelin Frick et al First Named Inventor **Examiner Name** 

for FY 2004 Patent fees are subject to annual revision. Applicant claims small entity status. See 37 CFR 1.27 Group / Art Unit **DEAV2002/0087 US NP** (\$) 770.00 Attorney Docket No. TOTAL AMOUNT OF PAYMENT METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued)

Check Credit Card Money Other None	3. A	ODITIO	NAL FI	EES	
Order  Deposit Account	Large E	ntity	Small E	ntity	
Deposit	Fee Code	Fee (\$)	Fee Code	Fee (\$)	
Account Number 18-1982	Couc	(4)	Couc	(4)	Fee Description Fee Paid
Deposit Account Aventis Pharmaceuticals Inc.			***	0.5	O I I I I I I I I I I I I I I I I I I I
Name The Commissioner is authorized to: (check all that apply)	1051	130	2051	65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or
Charge fee(s) indicated below Credit any overpayments	1052	50	2052	25	cover sheet
Charge any additional fee(s) during the pendency of this application	1053 1812	130 2,520	1053 1812	130 2,520	Non-English Specification For filing a request for reexamination
Charge fee(s) indicated below, except for the filing fee	1804	920*	1804	920*	Requesting publication of SIR prior to
to the above-identified deposit account	1805	1,840*	1805	1,840*	Examiner action  Requesting publication of SIR after
FEE CALCULATION	1803	1,040	1005	1,040	Examiner action
1. BASIC FILING FEE	1251	110	2251	55	Extension for reply within first month
Large Entity         Small Entity         Fee           Fee         Fee         Fee Description         Paid	1252	420	2252	205	Extension for reply within second month
Code (\$) Code (\$)					
1001 770 2001 375 Utility filing fee 770	1253	950	2253	465	Extension for reply within third month
1002 340 2002 165 Design filing Fee	1254 1255	1,480 2,010	2254 2255	725 985	Extension for reply within fourth month  Extension for reply within fifth month
1003   530   2003   260   Plant filing fee	1401	330	2401	160	Notice of Appeal
1005 160 2005 80 Provisional filing fee	1402	330	2402	160	Filing a brief in support of an appeal
	1402	290	2403	140	Request for oral hearing
SUBTOTAL (1) (\$)  2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	1451	1,510	Petition to institute a public use
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	1401	1,510	proceeding
Fee Extra from Fee	1452	110	2452	55	Petition to revive - unavoidable
Claims below Paid					
Total Claims 12 -20**= 0 x 18.00 = 0	1453	. 1,330	2453	650	Petition to revive - unintentional
Independent 1 - 3**= 0 x 86.00 = 0	1501	1,330	2501	650	Utility issue fee (or reissue)
Claims	1502	480	2502	235	Design issue fee
Multiple Dependent =	1503	640	2503	315	Plant issue fee
	1460	130	1460	130	Petitions to the Commissioner Petitions related to provisional
Large Entity Small Entity Fee Fee Fee Fee	1807	50	1807	50	applications
Code (\$) Code (\$) Fee Description	4000	400	4000	400	Cubalcales of Information Displaceurs
1202 18 2202 9 Claims in excess of 20	1806	180	1806	180	Submission of Information Disclosure Stmt
1201 86 2201 42 Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1203 290 2203 140 Multiple dependent claim, if not	1809	770	2809	375	(37 CFR § 1.129(a))
1204 86 2204 42 **Reissue independent claims over original patent	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent	1801	770	2801	375	Request for Continued Examination (RCE)
,	1802	900	1802	900	Request for expedited examination of a design application
SUBTOTAL (2) (\$)0.00	Other fee	e (specify)	1	_	dough approach
**or number previously paid, if greater; For Reissues, see above	*Reduce	ed by Basic	Filing Fe	e Paid	SUBTOTAL (3) (\$)

SUBMITTED BY		Complete (If applicable)				
Name (Print/Type)	Barbara E. Kurys	Registration No. (Attorney/Agent)	34,650	Telephone	(908) 231-2965	
Signature	Baban E. Luga			Date	12/12/03	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.